SINT · Sintx Technologies, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Despite the actions undertaken by management to improve liquidity and operating costs—including the divestiture of non-core operations, implementation of cost improvement initiatives, commercialization of newly cleared medical products, access to capital through the Company’s ATM program, and execution of the Armor facility sublease—management has concluded that substantial doubt remains regarding the Company’s ability to continue as a going concern for a period of at least 12 months from the date these condensed consolidated financial statements are issued.”View the 10-Q filed May 15, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.03M | $1.02M | $2.89M | $2.63M | $1.56M | $606K | $594K | $689K | $95K | $11.23M | $15.23M | $19.45M | $22.77M | $22.31M | |
| $547K | $557K | $811K | $784K | $265K | $449K | $475K | $551K | $56K | $6.35M | $3.78M | $6.25M | $7.91M | $7.05M | |
| $482K | $461K | $2.08M | $1.84M | $1.3M | $157K | $119K | $138K | $39K | $4.88M | $11.45M | $13.2M | $14.86M | $15.27M | |
| — | 45.28% | 71.91% | 70.16% | 83.02% | 25.91% | 20.03% | 20.03% | 41.05% | 43.43% | 75.19% | 67.87% | 65.25% | 68.43% | |
| $3.84M | $4.59M | $5.2M | $8.71M | $6.45M | $5.89M | $4.81M | $3.39M | $2.99M | $3.51M | $6.35M | $6.39M | $6.74M | $3.46M | |
| $621K | $242K | $614K | $1.14M | $1.34M | $1.29M | $683K | $430K | $135K | $325K | $10.35M | $12.42M | $18.69M | $16.38M | |
| $7.41M | $6.2M | $4M | $4.22M | $3.99M | $3.6M | $3.13M | $2.91M | $3.87M | $3.65M | $6.29M | $6.44M | $13.59M | $5.76M | |
| — | $19K | $5000 | $5000 | $5000 | $5000 | $5000 | $5000 | $4000 | $536K | $501K | $501K | $501K | $501K | |
| $12.03M | $11.18M | $16.12M | $15.2M | $12.63M | $10.78M | $8.62M | $6.73M | $13.16M | $7.49M | $22.98M | $25.24M | $39.02M | $25.6M | |
| -$11.55M | -$10.72M | -$14.05M | -$13.36M | -$11.34M | -$10.62M | -$8.5M | -$6.59M | -$13.12M | -$7.49M | -$11.54M | -$12.04M | -$24.17M | -$10.34M | |
| — | -1053.14% | -486.56% | -508.49% | -726.14% | -1752.48% | -1431.65% | -957.04% | -13806.32% | -66.67% | -75.76% | -61.9% | -106.16% | -46.32% | |
| $4.84M | — | — | — | — | — | — | — | — | — | — | — | $3.65M | $1.85M | |
| $1000 | — | — | — | — | — | — | — | — | — | — | — | $12K | $16K | |
| $652K | $357K | $3.02M | $5.1M | -$704K | $1.31M | $1.48M | $1.8M | $3.43M | $1.72M | -$3.23M | -$11.87M | -$8.42M | $2.05M | |
| -$10.89M | -$10.36M | -$11.02M | -$8.26M | -$12.04M | -$9.31M | -$7.03M | -$4.8M | -$9.69M | -$5.76M | -$14.76M | -$23.91M | -$32.58M | -$8.29M | |
| -$10.89M | -$10.36M | -$11.02M | -$8.26M | -$12.04M | -$9.31M | -$7.03M | -$4.8M | -$8.65M | -$9.33M | -$14.76M | -$23.91M | -$32.58M | -$8.29M | |
| — | -1018.07% | -381.85% | -314.39% | -771.24% | -1536.14% | -1183.33% | -696.23% | -9107.37% | -83.09% | -96.96% | -122.92% | -143.12% | -37.13% | |
| — | -$17.08M | -$11.02M | -$8.29M | -$16.49M | -$9.31M | -$16.59M | -$7.5M | -$22.55M | -$9329 | -$21.04M | -$23.91M | — | — | |
| -$1.13M | — | — | — | — | — | — | — | — | — | -$14.76M | -$23.91M | -$32.58M | -$8.29M | |
| USD/shares | — | -$6.16 | -$14.87 | -$443.47 | -$10,934.00 | -$7,540.00 | -$20,200.00 | -$96,400.00 | -$1,237,000.00 | -$62,600.00 | — | — | — | — |
| USD/shares | — | -$6.16 | -$15.19 | -$624.47 | -$12,162.00 | -$7,982.00 | -$21,600.00 | -$113,800.00 | -$1,534,600.00 | — | — | — | — | — |
| shares | — | 2.77M | 741.25K | 18.68K | 1508.05 | 1234.595 | 820.3278 | 77.7994 | 18.2301 | 148.9452 | 77.1868 | 18.1011 | 40.7999 | 26.7037 |
| shares | — | 2.77M | 744.78K | 21.79K | 1586.615 | 1253.505 | 872.3074 | 77.7994 | 19.1928 | 148.9452 | 77.1868 | 18.1011 | 40.7999 | 26.7037 |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2015–FY2025: $253K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 55 similar-size Medical Devices companies (of 145 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Product | $729,000 | $1,246,000 | $1,226,000 | $601,000 | $606,000 |
| Grant and Contract | $289,000 | $1,641,000 | $1,401,000 | $960,000 | — |